BOSTON, Feb. 2, 2022 /PRNewswire/ -- Environmental Impact
Acquisition Corporation (NASDAQ: ENVI), a publicly-traded special
purpose acquisition company, announced today that its business
combination with Greenlight Biosciences was approved in a
shareholder vote held yesterday, with 80.7% of shareholders
participating in the vote and 78.6% voting in favor of the
combination.
Subject to the satisfaction or waiver of the other customary
closing conditions, Environmental Impact Acquisition Corp.
anticipates closing the business combination today. In connection
with the closing, the company will change its name to GreenLight
Biosciences Holdings, public-benefit corporation, and the combined
company's shares of Class A common stock and public warrants are
expected to trade on the Nasdaq exchange beginning on February 3, 2022, under the ticker symbols "GRNA"
and "GRNA.WS," respectively.
"Today marks an important milestone, and I am thrilled to work
with our teams as we develop new applications for our RNA
platform," said Andrey Zarur, CEO of
GreenLight.
Investors include Serum Life Sciences, Fall Line Capital,
Viceroy Capital, S2G Ventures, Cormorant Asset Management,
Morningside Venture Investments, Hudson Bay Capital, BNP Paribas
Ecosystem Restoration Fund, The Jeremy and Hannelore Grantham
Environmental Trust, Continental Grain Company, Pura Vida
Investments LLC, Xeraya Capital, and MLS Fund II/Spruce.
Canaccord Genuity served as financial advisor and Latham &
Watkins LLP served as legal advisor to Environmental Impact
Acquisition Corp. SVB Leerink and Credit Suisse served as
financial and capital markets advisors to GreenLight and
co-placement agents on the PIPE transaction. Foley Hoag LLP is
served as legal advisor to GreenLight.
About GreenLight
Founded in 2008, GreenLight aims to
address some of the world's biggest problems by delivering on the
full potential of RNA for human health and agriculture. In human
health, this includes mRNA vaccines and therapeutics. In
agriculture, this includes RNA to protect honeybees and a
range of crops. The company's breakthrough cell-free RNA
manufacturing platform, which is protected by numerous patents,
allows for cost-effective production of RNA. GreenLight's human
health product candidates are in the pre-clinical stage, and its
product candidates for the agriculture market are in the early
stages of development or regulatory review. For more information,
visit https://www.greenlightbiosciences.com/
In August 2021, GreenLight
Biosciences announced plans to become publicly listed through a
business combination with Environmental Impact Acquisition Corp.
(Nasdaq: ENVI).
For more information, visit greenlightbiosciences.com
About Environmental Impact Acquisition
Corporation
Environmental Impact Acquisition Corp. is a
Special Purpose Acquisition Company. The Company is sponsored by CG
Investments Inc. VI, an affiliate of Canaccord Genuity, which
manages several investment vehicles.
Forward-Looking Statements
This press release contains
"forward-looking statements" within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995, with respect to the proposed transaction between GreenLight
Biosciences, Inc. ("GreenLight") and Environmental Impact
Acquisition Corp. ("ENVI"). These forward-looking statements
generally are identified by the words "believe," "project,"
"expect," "anticipate," "estimate," "intend," "strategy," "future,"
"opportunity," "plan," "may," "should," "will," "would," "will be,"
"will continue," "will likely result" and similar expressions. Many
factors could cause actual future events to differ materially from
the forward-looking statements in this press release, including but
not limited to the risk that the transaction may not be completed
in a timely manner or at all, which may adversely affect the price
of ENVI's securities and the effect of the announcement or pendency
of the transaction on GreenLight's business relationships,
operating results, and business generally. Forward-looking
statements speak only as of the date they are made. Readers are
cautioned not to put undue reliance on forward-looking statements,
and ENVI and GreenLight assume no obligation and do not intend to
update or revise these forward-looking statements, whether as a
result of new information, future events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/environmental-impact-acquisition-corporation-approval-obtained-greenlight-biosciences-set-to-begin-trading-under-nasdaq-grna-on-february-3-2022-301473860.html
SOURCE GreenLight Biosciences, Inc.
